Table 1.
Clinical differential diagnosis for primary cutaneous B-cell lymphoma (PCBCL) lesions according to subtype and anatomic location.
| Suspected clinical diagnosis | All PCBCL (n=172) | PCBCL subtype | P-value* | Anatomic location | P-value* | ||||
|---|---|---|---|---|---|---|---|---|---|
| PCMZL (n=99) | PCFCL (n=43) | PCDLBCL (n=30) | Head and neck (n=45) | Trunk (n=56) | Extremities (n=71) | ||||
| Cutaneous lymhpoma | 28 (16.3%) | 15 (15.2%) | 7 (16.3%) | 6 (20.0%) | 8 (17.8%) | 9 (16.1%) | 11 (15.5%) | ||
| Basal cell carcinoma | 30 (17.4%) | 11 (11.1%) | 13 (30.2%) | 6 (20.0%) | <0.05 | 14 (31.1%) | 12 (21.4%) | 4 (5.6%) | <0.01 |
| Squamous cell carcinoma | 10 (5.8%) | 1 (1.0%) | 6 (14.0%) | 3 (10.0%) | <0.01 | 4 (8.9%) | 2 (3.6%) | 4 (5.6%) | |
| Metastatsis | 6 (3.5%) | 1 (1.0%) | 3 (7.0%) | 2 (6.7%) | 1 (2.2%) | 3 (5.4%) | 2 (2.8%) | ||
| Dermatofibrosarcoma protuberans | 6 (3.5%) | 2 (2.0%) | 3 (7.0%) | 1 (3.3%) | 2 (4.4%) | 1 (1.8%) | 3 (4.2%) | ||
| Melanoma | 4 (2.3%) | 1 (1.0%) | 0 (0%) | 3 (10.0%) | <0.01 | 0 (0.0%) | 1 (1.8%) | 3 (4.2%) | |
| Other neoplasia/neoplastic process not specified | 32 (18.6%) | 15 (15.2%) | 10 (23.3%) | 7 (23.3%) | 10 (22.2%) | 9 (16.1%) | 13 (18.3%) | ||
| All skin malignancies | 94 (54.7%) | 41 (41.4%) | 31 (72.1%) | 22 (73.3%) | <0.001 | 31 (68.9%) | 32 (57.1%) | 31 (43.7%) | <0.05 |
| Cyst | 37 (21.5%) | 23 (23.2%) | 9 (20.9%) | 5 (16.7%) | 12 (26.7%) | 14 (25.0%) | 11 (15.5%) | ||
| Granulomatous process (Sarcoidosis, Granuloma annulare) | 27 (15.7%) | 17 (17.2%) | 5 (11.6%) | 5 (16.7%) | 6 (13.3%) | 7 (12.5%) | 14 (19.7%) | ||
*
P-value are mentioned if <0.05
PCBCL = primary cutaneous B-cell lymphoma; PCMZL = primary cutaneous marginal zone lymphoma; PCFCL = primary cutaneous follicle center lymphoma; PCDLBCL = primary cutaneous diffuse large B-cell lymphoma